
|Articles|March 9, 2010
- December 2009
- Volume 0
Do Insurers Spend Too Much on Administration and Too Little on Care?
Author(s)Onclive Team
Advertisement
Articles in this issue
almost 16 years ago
Amgen Honored for Best Pipeline & Best New Drugalmost 16 years ago
The Effect of New Treatments on Cancer-related Bone Lossalmost 16 years ago
Exercise Maintains Function, Improves QoL for Patients With Lymphomaalmost 16 years ago
Continuing Education Opportunities on the Webalmost 16 years ago
News Briefs & FDA Updatesalmost 16 years ago
News & Opinionalmost 16 years ago
Decline in Cancer Deaths No Reason to Get ComplacentAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
5



































